COSCIENS Biopharma Inc. (CSCI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSCIENS Biopharma Inc. (CSCI) has a cash flow conversion efficiency ratio of -0.627x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.45 Million) by net assets ($7.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is COSCIENS Biopharma Inc.'s balance sheet to measure how much of total assets are equity-financed.
COSCIENS Biopharma Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how COSCIENS Biopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CSCI cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
COSCIENS Biopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSCIENS Biopharma Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Weha Transportasi Indonesia TBK
JK:WEHA
|
0.069x |
|
Green Earth Group N.V.
AS:HWK
|
0.038x |
|
Suzhou Goldengreen Technologies Ltd
SHE:002808
|
-0.049x |
|
Impedimed Ltd
AU:IPD
|
-1.053x |
|
Tokyo Plast International Limited
NSE:TOKYOPLAST
|
-0.028x |
|
Slam Exploration Ltd.
V:SXL
|
-0.046x |
|
Creative Media & Community Trust Corporation
NASDAQ:CMCT
|
-0.101x |
|
MILA RESOUR. PLC LS-01
F:HN0
|
N/A |
Annual Cash Flow Conversion Efficiency for COSCIENS Biopharma Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of COSCIENS Biopharma Inc. from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see how much is COSCIENS Biopharma Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.16 Million | $-14.57 Million | -1.107x | -801.77% |
| 2023-12-31 | $21.04 Million | $-2.58 Million | -0.123x | -155.85% |
| 2022-12-31 | $23.79 Million | $5.23 Million | 0.220x | +73.55% |
| 2021-12-31 | $21.74 Million | $2.75 Million | 0.127x | -30.86% |
| 2020-12-31 | $19.06 Million | $3.49 Million | 0.183x | +363.33% |
| 2019-12-31 | $17.08 Million | $675.29K | 0.040x | +143.25% |
| 2018-12-31 | $17.04 Million | $-1.56 Million | -0.091x | -231.01% |
| 2017-12-31 | $17.93 Million | $1.25 Million | 0.070x | -68.00% |
| 2016-12-31 | $16.67 Million | $3.63 Million | 0.218x | -56.87% |
| 2015-12-31 | $5.68 Million | $2.87 Million | 0.506x | -50.46% |
| 2014-12-31 | $1.80 Million | $1.84 Million | 1.021x | -49.08% |
| 2013-12-31 | $229.62K | $460.21K | 2.004x | +123.19% |
| 2012-12-31 | $13.63K | $-117.82K | -8.642x | -653.59% |
| 2011-12-31 | $507.11K | $791.62K | 1.561x | +313.21% |
| 2010-12-31 | $-654.90K | $479.50K | -0.732x | -203.72% |
| 2009-12-31 | $-1.31 Million | $-925.47K | 0.706x | +23.17% |
| 2008-12-31 | $-1.59 Million | $-909.41K | 0.573x | +181.97% |
| 2007-12-31 | $1.57 Million | $-1.10 Million | -0.699x | -229.62% |
| 2006-12-31 | $260.64K | $140.59K | 0.539x | +158.09% |
| 2005-12-31 | $397.23K | $-368.84K | -0.929x | -14.94% |
| 2004-12-31 | $94.89K | $-76.65K | -0.808x | -537.56% |
| 2003-12-31 | $294.75K | $54.42K | 0.185x | +32.60% |
| 2002-12-31 | $-414.76K | $-57.75K | 0.139x | -78.26% |
| 2001-12-31 | $-714.40K | $-457.45K | 0.640x | +101.61% |
| 2000-12-31 | $-1.59 Million | $-506.44K | 0.318x | +101.16% |
| 1999-12-31 | $-1.31 Million | $-207.14K | 0.158x | -93.05% |
| 1998-12-31 | $-714.89K | $-1.62 Million | 2.273x | +574.75% |
| 1997-12-31 | $6.57 Million | $-3.14 Million | -0.479x | -101.57% |
| 1996-12-31 | $5.84 Million | $-1.39 Million | -0.237x | -- |
About COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reducti… Read more